TY - JOUR AU - Postow, M. A. AU - Chesney, J. AU - Pavlick, A. C. AU - Robert, C. PY - 2015 DA - 2015// TI - Nivolumab and ipilimumab versus ipilimumab in untreated melanoma JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1414428 DO - 10.1056/NEJMoa1414428 ID - Postow2015 ER - TY - BOOK AU - Larkin, J. AU - Chiarion-Silen, V. AU - Gonzalez, R. PY - 2017 DA - 2017// TI - Overall survival results from a phase III trial of nivolumab combined with ipilimumab in treatment-naïve patients with advanced melanoma (CheckMate 067) PB - Oral presentation presented at, The American Association of Cancer Research (AACR) Annual Meeting CY - Washington, DC ID - Larkin2017 ER - TY - JOUR AU - Reuss, J. E. AU - Kunk, P. R. AU - Stowman, A. M. AU - Gru, A. A. PY - 2016 DA - 2016// TI - Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report & review of the literature JO - J Immunother Cancer VL - 4 UR - https://doi.org/10.1186/s40425-016-0199-9 DO - 10.1186/s40425-016-0199-9 ID - Reuss2016 ER - TY - JOUR AU - Reddy, S. B. AU - Possick, J. D. AU - Kluger, H. M. AU - Galan, A. PY - 2017 DA - 2017// TI - Sarcoidosis following anti-PD-1 and anti-CTLA-4 therapy for metastatic melanoma JO - J Immunother VL - 40 UR - https://doi.org/10.1097/CJI.0000000000000181 DO - 10.1097/CJI.0000000000000181 ID - Reddy2017 ER - TY - JOUR AU - Iannuzzi, M. C. AU - Rybicki, B. A. AU - Teirstein, A. S. PY - 2007 DA - 2007// TI - Sarcoidosis JO - N Engl J Med VL - 357 UR - https://doi.org/10.1056/NEJMra071714 DO - 10.1056/NEJMra071714 ID - Iannuzzi2007 ER - TY - JOUR AU - Lower, E. E. AU - Weiss, K. L. PY - 2009 DA - 2009// TI - Neurosarcoidosis JO - Clin Chest Med VL - 29 UR - https://doi.org/10.1016/j.ccm.2008.03.016 DO - 10.1016/j.ccm.2008.03.016 ID - Lower2009 ER - TY - JOUR AU - Cleynen, I. AU - Vermeire, S. PY - 2012 DA - 2012// TI - Paradoxical inflammation induced by anti-TNF agents in patients with IBD JO - Nat Rev Gastroenterol Hepatol VL - 9 UR - https://doi.org/10.1038/nrgastro.2012.125 DO - 10.1038/nrgastro.2012.125 ID - Cleynen2012 ER - TY - JOUR AU - Ramstein, J. AU - Broos, C. E. AU - Simpson, L. J. AU - Ansel, K. M. AU - Sun, S. A. AU - Ho, M. E. AU - Woodruff, P. G. AU - Bhakta, N. R. AU - Christian, L. AU - Nguyen, C. P. AU - Antalek, B. J. PY - 2016 DA - 2016// TI - IFN-γ–producing T-helper 17.1 cells are increased in sarcoidosis and are more prevalent than T-helper type 1 cells JO - Am J Respir Crit Care Med VL - 193 UR - https://doi.org/10.1164/rccm.201507-1499OC DO - 10.1164/rccm.201507-1499OC ID - Ramstein2016 ER - TY - JOUR AU - von Euw, E. AU - Chodon, T. AU - Attar, N. AU - Jalil, J. PY - 2009 DA - 2009// TI - CTLA4 blockade increases Th17 cells in patients with metastatic melanoma JO - J Transl Med VL - 7 UR - https://doi.org/10.1186/1479-5876-7-35 DO - 10.1186/1479-5876-7-35 ID - von Euw2009 ER - TY - JOUR AU - Facco, M. AU - Cabrelle, A. AU - Teramo, A. AU - Olivieri, V. PY - 2011 DA - 2011// TI - Sarcoidosis is a Th1/Th17 multisystem disorder JO - Thorax VL - 66 UR - https://doi.org/10.1136/thx.2010.140319 DO - 10.1136/thx.2010.140319 ID - Facco2011 ER - TY - JOUR AU - Braun, N. A. AU - Celada, L. J. AU - Herazo-Maya, J. D. AU - Abraham, S. PY - 2014 DA - 2014// TI - Blockade of the programmed death-1 pathway restores sarcoidosis CD4(+) T-cell proliferative capacity JO - Am J Respir Crit Care Med VL - 190 UR - https://doi.org/10.1164/rccm.201401-0188OC DO - 10.1164/rccm.201401-0188OC ID - Braun2014 ER - TY - JOUR AU - Salama, A. K. AU - Moschos, S. J. PY - 2017 DA - 2017// TI - Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies JO - Ann Oncol VL - 28 ID - Salama2017 ER -